share_log

Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5

Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5

Cowen & Co.将全球血液疗法的评级下调至市场表现,将目标股价上调至68.5美元
Benzinga Real-time News ·  2022/08/09 04:58

Cowen & Co. analyst Ritu Baral downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and raises the price target from $67 to $68.5.

Cowen & Co. 分析师里图·巴拉尔将Global Blood Therapeutics(纳斯达克股票代码:GBT)的评级从跑赢大盘下调至市场表现,并将目标股价从67美元上调至68.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发